A detailed history of Allspring Global Investments Holdings, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 5,676 shares of DNLI stock, worth $140,083. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,676
Previous 6,097 6.91%
Holding current value
$140,083
Previous $141,000 17.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$20.96 - $31.05 $8,824 - $13,072
-421 Reduced 6.91%
5,676 $165,000
Q2 2024

Jul 26, 2024

SELL
$14.96 - $23.22 $942 - $1,462
-63 Reduced 1.02%
6,097 $141,000
Q1 2024

Apr 18, 2024

BUY
$15.83 - $23.35 $8,215 - $12,118
519 Added 9.2%
6,160 $126,000
Q4 2023

Jan 25, 2024

BUY
$16.2 - $23.18 $7,695 - $11,010
475 Added 9.19%
5,641 $121,000
Q3 2023

Oct 27, 2023

BUY
$20.63 - $30.17 $106,574 - $155,858
5,166 New
5,166 $106,000
Q2 2023

Jul 18, 2023

SELL
$23.37 - $32.96 $2,687 - $3,790
-115 Reduced 2.05%
5,493 $162,000
Q1 2023

Apr 13, 2023

BUY
$21.91 - $32.67 $51,839 - $77,297
2,366 Added 72.98%
5,608 $129,000
Q4 2022

Jan 23, 2023

SELL
$26.28 - $33.92 $1,865 - $2,408
-71 Reduced 2.14%
3,242 $0
Q3 2022

Oct 26, 2022

BUY
$25.97 - $38.53 $26,099 - $38,722
1,005 Added 43.54%
3,313 $101,000
Q2 2022

Jul 25, 2022

SELL
$20.88 - $35.19 $791,539 - $1.33 Million
-37,909 Reduced 94.26%
2,308 $67,000
Q1 2022

May 02, 2022

BUY
$29.0 - $47.27 $46,545 - $75,868
1,605 Added 4.16%
40,217 $1.29 Million
Q4 2021

Jan 28, 2022

BUY
$42.59 - $55.02 $1.64 Million - $2.12 Million
38,612 New
38,612 $1.72 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.